Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

Taiwan: A recent cohort study has highlighted the potential benefits of combining glucagon-like peptide-1 receptor agonists ...

Consumers taking GLP-1 drugs like Ozempic will need to adapt their shopping habits and diets, opening opportunities for food ...

In recent years, the landscape of diabetes and weight management has been significantly altered by the rise of glucagon-like peptide-1 (GLP-1) receptor agonists. These medications, initially developed ...

The study, published in the Journal of the American Medical Association (JAMA), found that SGLT2 inhibitors and GLP-1 ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...

If obesity is seen not just as a personal struggle but a disease of public health concern, we can look for systemic solutions ...

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.

Could taking tiny fractions of the normal prescribed dose of a medication offer a brilliant way to benefit from the drug, ...

Scientists have found a possible new way to reduce fat without relying on traditional dieting.A study in The American Journal ...